Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Highly selective c-Met inhibitor tepotinib plus gefitinib is active in Asian patients with c-Met+ NSCLC

Date

20 Dec 2015

Session

Poster presentation 2

Presenters

Ross Soo

Citation

Annals of Oncology (2015) 26 (suppl_9): 125-147. 10.1093/annonc/mdv532

Authors

R. Soo1, D. Kim2, J.C. Yang3, K. Park4, U. Stammberger5, H. Xiong6, C. Ihling7, Y. Wu8

Author affiliations

  • 1 Department Of Haematology-oncology, National University Health System, National University Cancer Institute, Singapore, 119228 - Singapore/SG
  • 2 Department Of Internal Medicine, Seoul National University Hospital (SNUH)-Yongon Campus, 110-744 - Seoul/KR
  • 3 Graduate Institute Of Oncology, National Taiwan University, Taipei/TW
  • 4 Innovative Cancer Medicine Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, 135-710 - Seoul/KR
  • 5 Global Research & Early Development; Early Clinical Development Oncology, Merck, 64293 - Darmstadt/DE
  • 6 Biostatistics, Merck Serono Pharmaceutical R&D Co., Ltd, Beijing/CN
  • 7 Biomarkers, Merck, 64293 - Darmstadt/DE
  • 8 Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, 510080 - Guangzhou/CN
More

Resources

Aim/Background

EGFR TKI resistance in pts with NSCLC with activating EGFR mutations (mt) is often due to c-Met abnormalities. The highly selective c-Met inhibitor tepotinib (MSC2156119J) had activity in a phase I trial in pts with advanced solid tumors. We report phase Ib data from a trial of tepotinib + gefitinib (Gef) in pts with Met+ NSCLC.

Methods

Asian adults with locally advanced/metastatic NSCLC and ECOG PS 0/1 were eligible. All pts had Met+ tumors (IHC 2 + /3+ overexpression using CONFIRM anti-total c-MET [SP44] rabbit MAb [Ventana]). C-Met amplification was assessed retrospectively using FISH (Dako MET/CEN-7 IQFISH Probe Mix (IUO); c-Met:CEP7 ratio ≥2). Tumor EGFR mt status was assessed retrospectively using therascreen® EGFR RGQ PCR Kit (QIAGEN). The phase Ib part had a 3 + 3 design; planned recruitment was 15-18 pts, who received tepotinib 300 or 500 mg/d p.o. + Gef 250 mg/d q3w. Primary objective: determine the RP2D of tepotinib for use with Gef; secondary objectives: PK, safety, and antitumor activity.

Results

As of 28/02/15, 15 pts had been enrolled: median age 63 years; male 40%; ECOG PS 0/1 2/13; median prior therapy regimens including an EGFR TKI 2. 3 pts received tepotinib 300 mg + Gef and 12 tepotinib 500 mg + Gef. 4 pts remain on treatment with tepotinib 500 mg + Gef. No DLTs were observed. 11 pts had tepotinib-related adverse events; the most common were asymptomatic amylase increase (n = 5), diarrhea (4), decreased appetite (4), dyspepsia (3). Grade 3/4 treatment-related adverse events included asymptomatic amylase (n = 3) or lipase increase (2), decreased neutrophil count (1), hyperglycemia (1). 3 and 2 of 6 pts with IHC 3+ tumors had a PR or SD, vs 1 and 5 of 8 pts with IHC 2+ tumors. The only pt with c-Met:CEP7 ratio ≥2 had a PR; 3 and 1 of 6 pts with ≥5 Met copies in >50% of cells had a PR or SD. 3/6 pts with c-Met:CEP7 ratio <2 had SD. EGFR mt status for 12 pts was T790M and L858R mt (n = 2), L858R mt alone (4), exon 19 deletion (2), no mt detected using therascreen® kit (2).

Conclusions

The RP2D of tepotinib with Gef in advanced NSCLC is 500 mg/day. Antitumor activity of the combination was observed in EGFR TKI-pretreated c-Met+ NSCLC. The phase II part will randomize ≈136 pts with T790M-/c-Met+ tumors who have failed first-line Gef to tepotinib 500 mg/d + Gef or cisplatin/pemetrexed.

Clinical trial identification

NCT01982955

Disclosure

R. Soo: consultancy/advisory role with AstraZeneca. Research funding from Merck Serono. J.C.-H. Yang: consultancy/advisory role and received honoraria from AstraZeneca; consultancy/advisory role with Merck Serono. K. Park: consultancy/advisory role with and received research funding from AstraZeneca

U. Stammberger, C. Ihling: employee of Merck KGaA. H. Xiong: employee of Merck Serono Pharmaceutical R&D Co., Ltd, Beijing, China. Y.-L. Wu: consultancy/advisory role with Merck Serono; honoraria from AstraZeneca. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings